In summary, we have described a branched multipeptide vaccine capable of stimulating a response to multiple CD8+ T cell epitopes from glioblastoma-TAAs such as ERBB2, BIRC5 and CD99. This evidence concerns the gene BIRC5 and glioblastoma.